Rajka 2024 Doha motto:
Global Perspectives on Atopic Dermatitis:
Uniting for a better Care
Keynote speakers
- Rayana BOU HAKA, WHO, Qatar
- Thomas BIEBER, Switzerland
- Mark HOON, NIH Bethesda, USA
- Carsten FLOHR, UK
- Uwe GIELER, Germany
- Emma GUTTMAN-YASSKI, USA
- Kenji KABASHIMA, Japan
- Brian KIM, USA
- Wei LI, China
- Georg STINGL, Austria
- Claudia TRAIDL-HOFFMANN, Germany
- Sabine WERNER, Switzerland
Program
Please note all sessions are based on Qatar time zone.
➜ Arabia Standard Time (AST) – UTC+3
Thursday, October 24th, 2024 — Pre-meeting
|
||
|---|---|---|
| 09:00 12:00 |
➜ CHECK THE PRE MEETING PROGRAM & INFORMATION HERE + REGISTER | |
Thursday, October 24th, 2024 — Symposium |
||
| 13:00 | Welcome addresses | |
| 13:00 |
Welcome to DohaMartin STEINHOFF, Qatar |
|
| 13:05 |
Welcome to DohaRayana BOU HAKA (WHO), Qatar |
|
| 13:15 |
ISAD President addressAlain TAÏEB, France |
|
| 13:20 |
Introduction into History of ISAD and Rajka meetingsJohannes RING, Germany |
|
| 13:30 | S1. |
Fundamental mechanisms of Pruritus in AD (45 min)
Conference Keynote Lecture |
| 13:30 |
Speaker IntroductionMartin STEINHOFF, Qatar |
|
| 13:30 | KL1 |
Keynote lecture: Pruritus research: present and future |
| 14:15 | S2. |
Pathophysiology of Atopic Dermatitis – Barrier and Epidermis (90 min)
Chairs: Ameen ALAWADHI, UAE / John C. SU, Australia |
| 14:15 | KL2 |
Keynote lecture: New aspects in the role of the epidermis in skin biologySabine WERNER, Switzerland |
| 14:45 | OL2 #435 |
The neuropeptide Endothelin-1 drives skin barrier disruptionRari LEO, Qatar |
| 15:00 | OL3 #324 |
Stratum corneum interleukin-2 in eczema at 1-month-old predicts later atopic dermatitisEriko MAEHARA, Japan |
| 15:15 | OL4 #459 |
Dupilumab Treatment Provides Sustained Improvement in Skin Barrier Composition and Function in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic DermatitisAnnie ZHANG, USA |
| 15:30 | PS1 | Poster presentations session 1 45 min Refreshment Break & Visit Exhibits |
| 16:15 | S3. |
Innate Immunity dysregulation (90 min)
Chairs: Georges NEMER, Qatar / Aysha AL-MALKI, Qatar Standard session with free communications |
| 16:15 | KL3 |
Keynote lecture: Cytokine based circuits and innate immunity in atopic dermatitisKenji KABASHIMA, Japan |
| 16:45 | OL5 #445 |
Methotrexate and ciclosporin improve skin biomarkers in childhood atopic dermatitis: results from the TREAT TrialHelen ALEXANDER UK |
| 17:00 | OL6 #419 |
Changes in oral microbiome of atopic dermatitis (AD) patients treated with dupilumab or upadacitinibGabriela ŻUK, Poland |
| 17:15 | S4. |
What’s New (65 min)
Chairs: Mohammed AL OTAIBI, Kuwait / Peter SCHMID-GRENDELMEIER, Switzerland / Delphine STAUMONT-SALLE, France Sponsors’ session |
| 17:15 | WL1 |
What’s New for Abrocitinib – Summary of Key Evidence for M2S Atopic DermatitisSpeaker from Pfizer: Erman GÜLER |
| 17:35 | WL2 |
In search of the Holy Grail in Atopic Dermatitis: Is dupilumab the first disease-modifying atopic dermatitis drug?Speaker from Sanofi: Ana ROSSI |
| 17:50 | WL3 |
Advancing patient care in immune-mediated skin diseases: The past, present and future of JAK inhibitionSpeaker for Abbvie: Mark KIRCHHOF |
| 18:05 | WL4 |
IL-13: Role in pathophysiology of atopic dermatitis and how to master the driver of inflammationSpeaker for Lilly: Thomas BIEBER |
| 18:20 | Refreshment Break & Visit Exhibits | |
| 19:30 | Welcome reception (open to all attendants) Sheraton Hotel Garden |
|
Friday, October 25th, 2024
|
||
| 08:30 | S5. |
Primary Prevention and Comorbidities (60 min)
Chairs: Peter SCHMID-GRENDELMEIER, Switzerland / Fatima Ahmed ALBREIKI, UAE / Lin MA, China Standard session with free communications |
| 08:30 | KL4 |
Keynote lecture: Does atopic dermatitis cause food allergy and what can we do about it?Carsten FLOHR, UK |
| 09:00 | OL7 #296 |
Maternal supplementation with prebiotics during pregnancy regulates colonization of the microbiota of high-risk children, but does not prevent atopic dermatitis at one year of age. The PREGRALL multicenter randomized control trialSébastien BARBAROT, France |
| 09:15 | OL8 #317 |
SERPINB7 mutations in hereditary palmoplantar keratosis and atopic dermatitisShan WANG, China |
| 09:30 | PS2 | Poster presentations session 2 30 min Refreshment Break & Visit Exhibits |
| 10:00 | S6. |
Adaptive Immunity dysregulation (60 min)
Chairs: Thomas BIEBER, Switzerland / Yousef BINAMER, Saudi Arabia / Fareed AHMAD, Qatar Standard session with free communications |
| 10:00 | KL5 |
Keynote lecture: New molecular and cellular players in the immunopathogenesis of ADGeorg STINGL, Austria |
| 10:30 | OL9 #433 |
The Critical Function of a Peripheral-induced Specific Skin-resident Treg cells in Allergen-Specific Immunotherapy for Atopic DermatitisKelun ZHANG, South Korea |
| 10:45 | OL10 #413 |
JAK1 inhibitor improves skin barrier function and associated proteomics in atopic dermatitis: a controlled real-world studyFang WANG, China |
| 11:00 | OL11 #300 |
Atopic Dermatitis: Untangling the Autoimmunity Novel Insights in the Era of Targeted ImmunotherapyHusham Yousuf BAYAZED, Iraq |
| 11:15 | Prayer time (60 min) Location: follow signs and program book. |
|
| 12:15 | 45 min Lunch break & Visit Exhibits | |
| 13:00 | S7. |
Pruritus and AD (90 min)
Chairs: Fang WANG, China / Muna AL MURRAWI, UAE / Joerg BUDDENKOTTE, Qatar |
| 13:00 | IL4 |
Neuroimmune circuits of pruritus in AD and therapeutic consequencesMartin STEINHOFF, Qatar |
| 13:30 | KL6 |
Keynote lecture: JAK-inhibitors for treatment of pruritus and prurigoBrian KIM, USA |
| 14:00 | OL12 #453 |
Nemolizumab was associated with rapid and significant improvements in itch and sleep in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)Andreas WOLLENBERG, Germany |
| 14:15 | OL13 #469 |
Efficacy and Safety of Upadacitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis Versus DupilumabChih-Ho HONG, Canada |
| 14:30 | OL14 #421 |
Atopic Dermatitis in Ethiopians: The Role of Rare FLG2 and NOD2 VariantsIsabel TAPIA, Sweden |
| 14:45 | OL15 #468 |
Improvement in Sleep and Quality of Life With Abrocitinib Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis and Severe Itch: A Pooled Analysis of 2 Randomized TrialsErman GÜLER, Turkey |
| 15:00 | OL16 #456 |
Dupilumab treatment provides sustained, consistent improvements of signs and symptoms over 1 year in pediatric patients with moderate-to-severe atopic dermatitisCarsten FLOHR, UK |
| 15:15 | PS3 | Poster presentations session 3 45 min Refreshment Break & Visit Exhibits |
| 16:00 | S8. |
Quality of Life & Comorbidities, Epidemiology (90 min)
Chairs: Johannes RING, Germany / Mariam AL NESF, Qatar / Haya AL-MANNAI, Qatar |
| 16:00 | KL7 |
Keynote lecture: AD – a stress disorder? The psychodermatological aspect!Uwe GIELER, Germany |
| 16:30 | IL5 |
Readibility of patient electronic materials for atopic dermatitis, itch and prurigo: is it of importance for patients’ well-being?Jacek SZEPIETOWSKI, Poland |
| 16:45 | OL17 #391 |
Atopic Dermatitis and Prurigo nodularis in The State of Qatar: Retrospective study from 2015-2023 on epidemiology, associated comorbidities, and Clinical Practice Guidelines (CPG) from Hamad Medical CorporationMohammed Nasser AL-ABDULLA, Qatar |
| 17:30 | OL18 #348 |
Multimorbidity in adults with atopic dermatitis in a population-based cohortLeon A. MILTNER, The Netherlands |
| 17:45 | OL19 #388 |
Hand eczema or atopic hand eczema: a single center, prospective study on clinical features, etiology, and diagnosis in ChinaYifeng GUO, China |
| 18:00 | Refreshment Break & Visit Exhibits | |
| 19:00 | Local Organizing Committee Cultural invitation — Katara (old cultural city) (03h00) | |
| 19:30 | Qatar symphony orchestra (classical music) | |
| 20:30 | President’s dinner at La Marsa restaurant Presentation of Rajka Medal, ILDS award and Poster prizes by Alain TAÏEB |
|
Saturday, October 26th, 2024
|
||
| 09:00 | S9. |
New Technologies and Atopic Dermatitis (90 min)
Chairs: Magdalena TRZECIAK, Poland / Roberto TAKAOKA, Brazil / Ayda AL-HAMMADI, Qatar |
| 09:00 | KL9 |
Keynote lecture: Climate change and ADClaudia TRAIDL-HOFFMANN, Germany |
| 09:30 | IL6 |
Methods and devices to assess pruritus in ADAkihiko IKOMA, Japan |
| 09:50 | OL20 #444 |
Skin Pathology Assessment with Optical Technologies (SPOT): Leveraging Optical Biomarkers for Sub-Clinical Atopic Dermatitis Severity MonitoringRobert BYERS, UK |
| 10:05 | OL21 #418 |
Shotgun Metagenomics Reveals Microbiome Dysbiosis in Dupilumab-Associated Head and Neck DermatitisWanjin KIM, South Korea |
| 10:20 | OL22 #448 |
The feasibility of using the Emerald Touchless Sensor for nighttime scratching and sleep quantificationAnnie ZHANG, USA |
| 10:35 | PS4 | Poster presentations session 4 30 min Refreshment Break & Visit Exhibits |
| 11:05 | S10. |
Topical therapies for Atopic Dermatitis: New advances (60 min)
Chairs: Andreas WOLLENBERG, Germany / Dirk J. HIJNEN, Netherlands / Ousmane FAYE, Mali |
| 11:05 | KL11 |
Keynote lecture: Phenotyping and endotyping AD: implications for disease managementThomas WERFEL, Germany |
| 11:20 | KL10 |
Keynote lecture: Disease modification in atopic dermatitis: fiction or soon reality?Thomas BIEBER, Switzerland |
| 11:50 | OL23 #346 |
General practitioners knowledge about use of topical steroids in atopic dermatitisFandresena Arilala SENDRASOA, Madagascar |
| 12:05 | OL24 #398 |
Topical Steroid Withdrawal in Atopic Dermatitis: Patient-Reported Characterisation from a Swedish Social Media QuestionnaireMikael ALSTERHOLM, Sweden |
| 12:20 | OL25 #383 |
Phage TherapyYousef DASHTI, Kuwait |
| 12:35 | 60 min Lunch break & Visit Exhibits | |
| 13:35 | S11. |
New Targeted and Systemic Therapies for Atopic Dermatitis (90 min)
Chairs: Kyu-Han KIM, South Korea / Medhat ASKAR, Qatar |
| 13:35 | KL12 |
Keynote lecture: Biologics in AD: an updateWei LI, China |
| 14:05 | OL26 #338 |
HADS anxiety and depression scores improved in Japanese patients with moderate-to-severe atopic dermatitis following lebrikizumab treatment: 68-week results from a randomized, double-blind, placebo-controlled Phase 3 trial (ADhere-J)Martin DOSSENBACH, USA |
| 14:20 | IL7 |
New targeted therapies for ADAndreas WOLLENBERG, Germany |
| 14:40 | OL27 #302 |
A novel antimicrobial peptide catestatin modulates skin barrier and immune responses in atopic dermatitisGe PENG, Japan |
| 14:55 | OL28 #425 |
Dupilumab injection intervals in Adult Atopic Dermatitis Patients: Experiences in Korean PatientsJong Hee LEE, South Korea |
| 15:10 | IL8 |
JAK-inhibitors for treatment of ADKilian EYERICH, Germany |
| 15:30 | PS5 | Poster presentations session 5 40 min Refreshment Break & Visit Exhibits |
| 16:10 | S12. |
Future treatments of AD (90 min)
Chairs: Alain TAÏEB, France / Kenji KABASHIMA, Japan / Sara AL-KHAWAGA, Qatar |
| 16:10 | KL13 |
Keynote lecture: Future therapy of AD: A precision medicine perspectiveEmma GUTTMAN-YASSKI, USA |
| 16:40 | OL29 #423 |
Efficacy of Combined Topical Pimecrolimus, Antibiotics, and Topical Ivermectin Therapy for Rosacea in 39 Patients Among 315 Receiving Dupixent: A Detailed AnalysisKim HYUN JUNG, South Korea |
| 16:55 | OL30 #349 |
Combined dupilumab and allergen‐specific immunotherapy in severe refractory atopic dermatitisJemin KIM, South Korea |
| 17:10 | OL31 #451 |
Development of an Emulgel for the Effective Treatment of Atopic Dermatitis in children and adults: Biocompatibility and Clinical InvestigationAlmudena GÓMEZ-FARTO, Spain |
| 17:25 | OL32 #442 |
Dupilumab Efficacy and Safety up to 2 Years in Children Aged 6 Months to 5 Years With Atopic DermatitisJohn C. SU, Australia |
| 17:40 | IL9 |
—Diamant THACI, Germany |
| 17:40 | Closing ceremony (20 min) | |
Best poster/presentation awards, local best postersMartin STEINHOFF, Qatar |
||
Next Rajka Symposium: Melbourne, AustraliaJohn C. SU, Australia |
||
Closing remarksAlain TAÏEB, France |
||
